Use your voice to help secure continued Federal funding for important diabetes research, inform health and regulatory policy, and improve the quality of life for those affected by T1D – until we find a cure.
Health Insurance: Explained
In addition to assistance with cost of insulin, JDRF’s T1D Health Insurance Guide helps families navigate topics including prior authorizations, denials and appeals, and applying for an exception.
Delegates selected from across the country and our five affiliates travel to Washington, D.C., to meet with lawmakers to share their personal stories, and explain the importance of Federal funding in T1D research.
Coverage to Control
Join in the movement to persuade insurance companies to provide predictable and reasonable costs for insulin, freedom to choose your pump, and coverage for artificial pancreas systems.
Learn more about policies and programs that impact the T1D community.
JDRF has set an ambitious advocacy agenda for 2023 to ensure people have access to the most effective T1D treatments and therapies.
JDRF is committed to accelerating the development of drugs and devices that enable people with T1D to live longer, healthier lives, including next generation artificial pancreas systems.
JDRF strongly advocates for the highest possible funding levels for the National Institutes of Health (NIH) and U.S. Food and Drug Administration (FDA).
JDRF is fighting for protections for pre-existing conditions and other health reform principles.
Insulin Access and Innovation
JDRF is committed to making insulin more affordable and accessible, while ensuring the next generation of insulins continue to develop.
Thanks to extensive advocacy by JDRF and other stakeholders and strong bipartisan support from Congress, continuous glucose monitors (CGM) are now eligible for Medicare coverage.
Special Diabetes Program
Our advocacy helped secure nearly $2.8 billion for T1D research since 1997 through the Special Diabetes Program (SDP).
T1D Outcomes Program
JDRF is working with the community to better define clinical meaningful T1D outcomes beyond HbA1c.
Biosimilar Insulin Principles
JDRF is encouraging health plans, employer benefit administrators, and regulators to adopt these principles, which will ensure patients and providers are supported in the rollout of insulin biosimilars.
What is Grassroots Advocacy?
Writing and Calling
Members of Congress through initiatives
with lawmakers and their staff
our stories of living with T1D
others to raise their voices